HER2-Targeted Treatments for NSCLC: Introducing Zongertinib
Non-small-cell lung cancer (NSCLC) comprises approximately 85% of all diagnosed lung cancers, and harbors oncogenic driver mutations in genes such as EGFR, ALK, KRAS, ERBB2, BRAF, ROS1, NTRK1/2/3, RET, and MET. ERBB2 encodes for HER2, a receptor …